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Abstract
Introduction: In this work we report on the possible effect of the medical therapy on CDT concentration in a chronic alcohol abuser, with known 
medical history (July 2007 – April 2012) and alcohol abuse confirmed by relatives.
Case history: At the end of 2007, patient displayed the following laboratory results: AST 137 U/L, ALT 120 U/L, GGT 434 U/L, MCV 101 fL and CDT 
3.3%. On December 2007, after double coronary artery bypass surgery, he began a pharmacological treatment with amlodipine, perindopril, atorva-
statin, isosorbide mononitrate, carvedilol, ticlopidine and pantoprazole. In the next months, until may 2011, the patient resumed alcohol abuse, as 
confirmed by relatives; however, CDT values were repeatedly found negative (0.8% and 1.1%) despite elevated transaminases and GGT, concurrent 
elevated ethyl glucuronide concentration (> 50 mg/L) and blood alcohol concentration (> 1 g/L). Alcohol consumption still continued despite incre-
asing disulfiram doses ordered by an Alcohol Rehab Center. On May 2011, the patient was transferred to a private medical center where he currently 
lives.
Conclusions: This study suggests the possibility that a medical therapy including different drugs may hamper the identification of chronic alcohol 
abusers by CDT.
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A shift in the carbohydrate composition of trans-
ferrin towards glycoforms with a lower degree of 
glycosylation is frequently observed in alcohol 
abuse (1). Carbohydrate-deficient transferrin (CDT), 
indicating collectively the glycoforms of human 
transferrin with 0-2 terminal sialic acid residues, 
namely asialo-, monosialo- and disialotransferrin, 
is considered the most specific biochemical mark-
er for detecting chronic alcohol abuse and for 
monitoring abstinence during treatment (1). Be-
cause of its application to the legal medicine con-
text, such as workplace safety monitoring or in 
traffic medicine, where a positive result may ham-
per driver’s license renewal or regranting, many 
studies have investigated the factors possibly as-
sociated to CDT false positivity or CDT specificity 
(2-4). To overcome the lack of standardization still 
affecting CDT analysis (5), the Working Group on 
Standardization of CDT measurement (IFCC-WG-
CDT) has suggested to use disialotransferrin (DST) 
as the primary target molecule for CDT testing, 
measured by HPLC and expressed as relative 
amount (%CDT) of total transferrin to compensate 
for variable levels of total transferrin concentration 
(6). Accordingly, studies assessing CDT by HPLC, 
and following IFCC-WG-CDT recommendations, 
have shown that many of the physiological and 
pathological factors previously supposed to affect 
CDT specificity were indeed due to unspecific 
methodologies applied for CDT analysis (3).
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Conversely, CDT sensitivity still remains a contro-
versial issue with only a minority of studies report-
ing on factors associated to false negative results 
in chronic alcohol abusers.
Although drugs could theoretically affect CDT, few 
studies have investigated the role of pharmaco-
logical therapy on CDT levels (7); in particular, 
while enzyme-inducing antiepileptic drugs were 
reported to increase CDT, angiotensin II receptor 
antagonists (sartans) have been shown to lower 
CDT values (3,8). However, major limitations of 
these studies include under-reported alcohol con-
sumption, use of a single determination of the bi-
omarker and unavailability of clinical data. The 
study of the possible influence of pharmacological 
therapy on CDT levels could be valuable in many 
situations: among others, CDT is used to detect 
chronic alcohol consumption in subjects applying 
for driver’s license renewal or regranting and a 
growing number of people, mainly in the elderly, 
are now under polytherapy; moreover, CDT is fre-
quently used to assess patients suffering from al-
coholic cirrhosis, and often under polytherapy, as 
potential candidates for orthotopic liver transplan-
tation.
Aim of this study was to report on the possible ef-
fect of the pharmacological therapy on CDT levels 
in a chronic alcohol abuser, with known medical 




The patient investigated in this study is a male, 65 
years old, body mass index = 26.8, former smoker 
(more than 20 years of abstinence), with an history 
of mild hypertension (therapy with ramipril dis-
continued), gastric ulcer, without clinical evidence 
of liver cirrhosis or fibrosis. Alcohol consumption 
(beer: > 1000 mL per day and wine: 500-1000 mL 
per day) has been frequently witnessed and re-
ported by family members and neighbours and 
has been estimated as 90-150 g ethanol per day.
Blood samples were collected in Becton Dickinson 
Vacutainer Plastic tubes (BD Diagnostics, Sparks, 
MD) containing the appropriate additive, while 
urine samples were collected in sterile plastic 
tubes.
Methods
CDT was measured by %CDT kit by HPLC (Bio-Rad, 
Munich, Germany). Briefly, samples were prepared 
(pre-treatment includes iron-saturation with Ferric 
Chloride (FeCl3) and lipoprotein precipitation with 
dextransulfate) according to manufacturer’s in-
structions and 100 µL were injected in a Agilent 
1200 HPLC system (Agilent Technologies, Santa 
Clara, CA) with anion-exchange cartridge kept at 
40 °C, using a ternary buffer gradient with a flow 
of 1.4 mL/min and detection at 460 nm. After peak 
integration, CDT, calculated as the ratio between 
the area of the disialotransferrin glycoform and 
that of all transferrin glycoforms, was then ex-
pressed as percentage (%) of disialotransferrin to 
total transferrin area (9) (laboratory cut-off: 2.0%). 
The method does not allow estimation of circulat-
ing total transferrin levels. Two sets of controls (low 
control: 0.7-2.1%; high control: 2.6-4.4% also sup-
plied by Bio-Rad) were run as triplicates, and al-
ways found within the range declared by the man-
ufacturer. Total precision (CV%) at mean CDT levels 
of 1.14% and 6.25% was respectively 5.9% and 
2.2%, with a recovery of 99% and a detection limit 
of 0.3%. This HPLC-based commercial kit was re-
cently validated by Helander in comparison with 
the reference candidate method and found to be 
appropriate both for routine and confirmatory CDT 
analysis (9).
Aspartate aminotransferase (AST), alanine ami-
notransferase (ALT) and gamma-glutamyltrans-
ferase (GGT) were measured on ADVIA 2400 (Sie-
mens Healthcare, Milan, Italy). Mean corpuscular 
volume (MCV) was assessed by a XE-2100 appara-
tus (Sysmex Europe GmbH, Norderstedt, Germa-
ny). Ethanol was evaluated after collection by Ax-
sym (Abbott Laboratories, Abbott Park, IL) and 
confirmed by headspace gas chromatography 
mass spectrometry (HS-GC-MS) (PerkinElmer, San-
ta Clara, CA). Ethyl glucuronide in urine (laboratory 
cut-off 0.5 mg/L) was assessed by DRI-EtG Enzyme 
Immunoassay (Microgenics-Thermo Fischer, Milan, 
Italy) on ADVIA 2400 (Siemens Healthcare, Milan, 
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Italy). Analytical performances were evaluated by 
taking part to GTFCh Proficiency Test (Gesellschaft 
für Toxikologische und Forensische Chemie). An 
informed consent was obtained by both patient 
and relatives.
Case history
The patient investigated in this study is a known 
alcohol abuser, whose alcohol consumption (90-
150 g of ethanol/day) has been frequently wit-
nessed and reported by family members and 
neighbours. At the end of 2007, the patient dis-
played following laboratory results: AST 137 U/L, 
ALT 120 U/L, GGT 434 U/L, MCV 101 fL and CDT 
3.3%, confirming chronic alcohol abuse. On De-
cember 2007, after double coronary artery bypass 
surgery, he began a pharmacological permanent 
treatment with amlodipine (calcium channel 
blocker) 5 mg per day, perindopril (ACE inhibitor) 
2.5 mg per day, atorvastatin (statin) 10 mg per day, 
isosorbide mononitrate (nitrate) 3 x 40 mg per day, 
carvedilol (beta blocker) 6.25 mg per day, ticlopi-
dine (inhibitor of platelet aggregation) 250 mg per 
day (2009) changed to 2 x 250 mg per day (2010), 
pantoprazole (gastric acid pump inhibitor) 20 mg 
per day. After six months of reduced alcohol con-
sumption (March to August 2008: normal ami-
notransferase activities and GGT slightly increased), 
he gradually resumed alcohol abuse; however, de-
spite witnessed daily large alcohol consumption, 
on July 2009 the patient displayed CDT 0.8%. Two 
months later, the patient was admitted to the trau-
ma service for a hip fracture after a fall; blood alco-
hol concentration, measured 16 hours after the 
admission, was 0.8 g/L, with aminotransferases 
Figure 1. Medical history of the patient investigated.
Upper panel: clinical and therapy data (hatched, dark grey and light grey bars indicate respectively witnessed alcohol consumption, 
admission to hospital and admission to a private medical centre).
Middle panel: CDT trend in the period investigated (3.3% - 0.8% - 1.1%).
Lower panel: GGT (white circles), ALT (light grey circles) and AST (dark grey circles) trends in the period investigated. BAC (blood alco-
hol concentration) and urin-EtG (urinary ethyl glucuronide) concentrations were reported in the upper panel (arrows). URL indicates 
the upper reference limit for GGT (50 U/L), AST (40 U/L) and ALT (40 U/L). x 1, x 5, x 11 indicate respectively the URL, 5 and 11 times the 
URL.
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slightly increased. Three months after discharge 
(March 2010), the patient displayed AST 58 U/L, ALT 
72 U/L, GGT 229 U/L, MCV 95 fL. On January 2011, 
he was persuaded by the family to undergo, with-
out notice, to CDT test: despite CDT negative result 
(1.1%), the patient displayed GGT 555 U/L, MCV 101 
fL and concurrent significantly high urinary ethyl-
glucuronide concentration (> 50 mg/L), measured 
three times a week for two consecutive weeks. 
One month later (February 2011) the patient decid-
ed to get help from Alcohol Rehab Center and to 
begin treatment with disulfiram. Despite increas-
ing disulfiram doses, the patient continued to 
drink, as reported to the Rehab Center by family 
members and further confirmed by repeatedly el-
evated ethylglucuronide urinary concentration 
(still > 50 mg/L). On May 2011 the patient was ad-
mitted to the emergency service for acute coro-
nary syndrome (ACS), displaying 4 hours after ad-
mission a blood alcohol concentration of 1.2 g/L. 
Finally, after discharge, he was transferred to a pri-
vate medical center where he currently lives.
Discussion
According to many authors, one of the main pit-
falls still affecting CDT testing is low sensitivity 
(10,11). Many factors have been reported to affect 
diagnostic sensitivity of serum CDT as a marker of 
alcohol abuse, namely age, sex, body mass, hyper-
tension, drugs, smoking and drinking pattern (1). 
However, many contrasting data are available in 
literature and sensitivity of CDT still remains a con-
troversial issue (12). A reason for this may be found 
in the plethora of analytical methods, cut-off and 
target molecules used to evaluate CDT in alcohol 
abusers (1,5,13-15).
Although this work is based upon a single clinical 
case, however it presents several strengths: CDT 
was measured with a HPLC method which has 
been recently shown to be appropriate both for 
routine and confirmatory CDT analysis (9); CDT, ac-
cording to IFCC-WG-CDT recommendations, was 
reported as disialotransferrin (DST), the primary 
target molecule for CDT testing, and expressed as 
relative amount (%CDT) of total transferrin (6); the 
alcohol abuse was repeatedly witnessed by rela-
tives and neighbours; it was documented by ele-
vated CDT, ethylglucuronide and by high blood al-
cohol concentrations during several admissions to 
the emergency unit; finally it was confirmed by an 
Alcohol Rehab Center which even treated the pa-
tient with disulfiram. Moreover, both clinical histo-
ry and therapy were available.
This study suggests the possibility that a medical 
therapy including different drugs may hamper the 
identification of chronic alcohol abusers by CDT. At 
least for this case, this effect does not depend ei-
ther on irregular alcohol intake (common to sub-
jects abstaining from drinking few weeks before 
CDT testing), as confirmed by relatives’ witness 
and concurrent elevated ethylglucuronide levels, 
or on analytical errors (sample substitution) or ab-
normalities (CDT variants), since CDT analysis was 
confirmed by a second analysis (different sample 
preparations) and performed by a validated HPLC 
method. Although circulating total transferrin con-
centration was not available, it is unlikely that the 
decreased CDT levels are due to decreased trans-
ferrin concentration, possibly induce by therapy or 
liver disease, since CDT was expressed as percent-
age of disialotransferrin to total transferrin area 
which allows for correction for variable transferrin 
concentrations. Moreover, the observation that 
the patient displayed elevated CDT levels before 
treatment (3.3%) but normal CDT levels in different 
occasions (0.8% and 1.1%) after treatment, despite 
unchanged alcohol consumption, suggests a link 
between CDT negativity and pharmacological 
therapy. Although detailed liver function data 
were not available (patient did not undergo liver 
biopsy during several hospital admissions), it is un-
likely that CDT decrease was due to the presence 
of end-stage liver disease or cirrhosis, since it has 
been shown that these conditions may instead 
cause false positivite CDT results (actually in a very 
small percentage of cases if a validated HPLC 
method is used) (3).
Since little is known on the exact mechanisms by 
which alcohol increases CDT in chronic abusers (1), 
from a theoretically point of view it is possible that 
drugs may affect CDT levels by different mecha-
nisms (8). However, the identification of these fac-
tors is behind the scope of this report, and requires 
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a confirmation by both high-sample size studies as 
well as experimental studies in order to evaluate 
drug, dosage and possibly mechanism.
Recent data, obtained by validated CDT methods, 
suggest that, despite what has been previously re-
ported in literature, only a minority of factors may 
lead to false positivity, namely liver diseases, preg-
nancy or glycosylation disorders (3,16). On the oth-
er hand, false negativity to CDT testing is still to be 
elucidated. With this regard, this clinical case, al-
though with limited evidence, seems to indicate 
that, in addition to known factors (inappropriate 
methods, elevated cut-offs or patient’s abstinence 
in the weeks before testing) medical history could 
also play a role in CDT sensitivity, suggesting that 
there may be situations where the concurrent use, 
of additional alcohol biomarkers may help in prop-
erly identify alcohol abusers.
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